11,556 results match your criteria Journal of cardiovascular pharmacology[Journal]


Number of ECG Replicates Influences the Estimated QT Prolonging Effect of a Drug.

J Cardiovasc Pharmacol 2019 Feb 6. Epub 2019 Feb 6.

Centre for Human Drug Research, Leiden, the Netherlands.

Introduction: The present analysis addressed the effect of the number of ECG replicates extracted from a continuous ECG on estimated QT interval prolongation for different QT correction formulas.

Methods: For one hundred healthy volunteers, who received a compound prolonging the QT interval, 18 ECG replicates within a 3 minute window were extracted from 12-lead Holter ECGs. Ten QT correction formulas were deployed and the QTc interval was controlled for baseline and placebo and averaged per dose level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000657DOI Listing
February 2019

The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse.

J Cardiovasc Pharmacol 2019 Feb 8. Epub 2019 Feb 8.

VCU Pauley Heart Center.

Background: Activation of the NLRP3 inflammasome is a primary driver of sterile inflammation in response to myocardial ischemia reperfusion. Pharmacologic inhibitors of the NLRP3 inflammasome are being developed. We proposed that OLT1177 (dapansutrile), a novel NLRP3 inflammasome inhibitor, could preserve myocardial function after ischemia reperfusion injury in the mouse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000658DOI Listing
February 2019

Prognostic Impact of Angiotensin Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and ICD Therapies.

J Cardiovasc Pharmacol 2019 Feb 8. Epub 2019 Feb 8.

First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, European Center for AngioScience (ECAS), and DZHK (German Center for Cardiovascular Research) partner site Heidelberg/Mannheim, Mannheim, Germany.

This study sought to assess the prognostic impact of treatment with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) on recurrences of ventricular tachyarrhythmias in recipients of implantable cardioverter defibrillators (ICD).Using a large retrospective registry including consecutive ICD recipients with documented episodes of ventricular tachycardia (VT) or fibrillation (VF) from 2002 to 2016, those patients treated with ACEi/ARB were compared to patients without (non-ACEi/ARB). The primary prognostic endpoint was first recurrences of ventricular tachyarrhythmias and related ICD therapies at 5 years. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9856
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000659DOI Listing
February 2019
3 Reads

Relationships of Statins Therapy and Hyperlipidemia with the Incidence, Rupture, Post-repair Mortality and All-cause Mortality of Abdominal Aortic Aneurysm and Cerebral Aneurysm: A Meta-analysis and Systematic Review.

J Cardiovasc Pharmacol 2019 Jan 25. Epub 2019 Jan 25.

Department of Obstetrics, Zaozhuang Municipal Hospital, Zaozhuang, China.

Statins have been suggested in previous studies to play a protective role in experimental cerebral aneurysm (CA) models; however, no evidence supports that the application of statins can protect against aneurysm rupture in humans, and the risks of lipid levels and aneurysms remain unknown. Therefore, this meta-analysis aimed to summarize and update the epidemiological evidence to systematically assess the relationships of statins therapy and hyperlipidemia with the incidence, rupture, post-repair mortality and all-cause mortality of abdominal aortic aneurysm (AAA) and CA. Related studies were initially retrieved from the electronic databases PubMed, Embase and Cochrane library from inception to August 4, 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000653DOI Listing
January 2019
1 Read

Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation: Meta-Analysis of Safety and efficacy1.

J Cardiovasc Pharmacol 2019 Jan 25. Epub 2019 Jan 25.

Tenth People's Hospital of Tongji University, Shanghai, China.

Background: Radiofrequency ablation (RFA) and antiarrhythmic drugs (AAD) are the main treatments used for atrial fibrillation (AF). In recent years, a number of articles comparing the two treatments have begun to emerge. Though, the influence of follow-up time in the meta-analysis was not considered in these articles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000654DOI Listing
January 2019
3 Reads

Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.

J Cardiovasc Pharmacol 2019 Jan 25. Epub 2019 Jan 25.

Department of Cardiology, The First Affiliated Hospital, Jinan University, Guangzhou 510630, China.

Aims: To evaluate the efficacy and safety of using genetic information to guide warfarin dosing in the Chinese population.

Methods: This meta-analysis was conducted among the published, randomized, controlled trials (RCTs) in the Chinese population comparing genotyped-guided warfarin dosing (PG group) with clinical or standard warfarin dosing (STD group). RCTs published on or before January 2018 were identified using the PubMed, Embase, Cochrane Library, CNKI, Chinese VIP database and Chinese Wanfang databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000656DOI Listing
January 2019

A Novel and Highly Potent Urotensin II Receptor Antagonist Inhibits Urotensin II-Induced Pressure Response in Mice.

J Cardiovasc Pharmacol 2019 Jan;73(1):15-21

Rare Disease & LCM Laboratories, Daiichi-Sankyo Co, Ltd, Shinagawa-ku, Tokyo, Japan.

This study was designed to characterize the pharmacological profile of DS37001789, which is a structurally novel piperazine derivative that acts as urotensin II (U-II) receptor antagonist. DS37001789 inhibited [I]-U-II binding to human GPR14, U-II receptor, with an IC50 value 0.9 nM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000618DOI Listing
January 2019
10 Reads

The antihypertrophic effects of nebivolol on neonatal cardiomyocyte hypertrophy models.

Authors:
Isil Ozakca

J Cardiovasc Pharmacol 2018 Dec 27. Epub 2018 Dec 27.

Ankara University, Faculty of Pharmacy, Department of Pharmacology, Ankara, TURKEY.

The antihypertrophic effect of nebivolol over cardioselective beta-blockers (β-blockers) is attributed to the activation of cardiac nitric oxide signaling. However, the precise role of nebivolol on hypertrophied cardiomyocytes remains unclear. In the current study, in vitro cardiomyocyte hypertrophy model was induced with isoprenaline (10μM), angiotensin II (1μM) and phenylephrine (20μM) in neonatal cardiomyocytes isolated from 0-2 days old Sprague-Dawley rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000647DOI Listing
December 2018
1 Read

Efficacy of Minimally Invasive Intervention in Patients With Acute Cerebral Infarction.

J Cardiovasc Pharmacol 2019 Jan;73(1):22-26

Department of Neurosurgery, Shanxi Provincial People's Hospital, Taiyuan City, Shanxi Province, China.

Our aim was to explore the efficacy of minimally invasive intervention in patients with acute cerebral infarction (ACI). Seventy patients with ACI were randomized into either an experimental group or a control group. In addition to the regular treatment, patients in the control group also received intravenous thrombolysis with urokinase, while patients in the other group underwent percutaneous transluminal cerebral angioplasty and stenting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000625DOI Listing
January 2019
4 Reads

Atorvastatin improves doxorubicin-induced cardiac dysfunction by modulating Hsp70, Akt and MAPK signalling pathways.

J Cardiovasc Pharmacol 2018 Dec 10. Epub 2018 Dec 10.

Department of Cardiology, The Second Hospital of Shandong University, Jinan, China.

Atorvastatin is a lipid-regulating drug that is commonly used in clinical practice and can stabilize plaques. Increasing evidence shows that statins have anti-heart failure effects, but their specific mechanism is not clear. The purpose of this study was to investigate the cardioprotective effects of atorvastatin on heart failure in rats and its mechanism. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9857
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000646DOI Listing
December 2018
1 Read

Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.

J Cardiovasc Pharmacol 2019 Feb;73(2):118-124

Servicio de Cardiología, Hospital Universitario Gregorio Marañón, CIBERCV, Madrid, Spain.

Sacubitril/valsartan (SV) is a new therapy in heart failure with reduced ejection fraction. Our aim was to determine the efficacy and safety of this drug daily clinical practice. We performed a multicenter registry in 10 hospitals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000641DOI Listing
February 2019
13 Reads

Population pharmacokinetic analysis of bisoprolol in patients with acute coronary syndrome.

J Cardiovasc Pharmacol 2018 Dec 10. Epub 2018 Dec 10.

Department of Pharmacology and Toxicology, Faculty of Medicine, University of Niš, Serbia.

To date, many questions about the extent and cause of pharmacokinetic variability of even the most widely studied and prescribed β1-adrenergic receptor blockers, such as metoprolol and bisoprolol, remain unanswered. Given that there are still no published population pharmacokinetic (PopPK) analyses of bisoprolol in routinely treated patients with acute coronary syndrome (ACS), the aim of this study was to determine its PK variability in 71 Serbian patients with ACS. PopPK analysis was carried out using a non-linear mixed effects model (NONMEM), version 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000644DOI Listing
December 2018
4 Reads

Comparison of Candesartan and Angiotensin-(1-7) Combination and Mito Tempo Treatment for Normalizing Blood Pressure and Sympathovagal Balance in (Mren2)27 Rats.

J Cardiovasc Pharmacol 2018 Dec 10. Epub 2018 Dec 10.

Hypertension & Vascular Research, Cardiovascular Sciences Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157.

Hypertensive transgenic (mRen2)27 rats exhibit impaired baroreflex sensitivity (BRS) for control of heart rate (HR). Intracerebroventricular (ICV) infusion of Ang-(1-7) improves indices of vagal BRS independent of lowering mean arterial pressure (MAP), while AT1 receptor blockade normalizes MAP and indices of sympathetic tone without correcting the vagal BRS. Scavenging cellular reactive oxygen species (ROS) with tempol in brain fails to correct either hypertension or sympathovagal balance in these animals, despite reports that mitochondrial ROS contributes to Ang II-infusion hypertension. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9857
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000645DOI Listing
December 2018
10 Reads

The Titration and Tolerability of Sacubitril/Valsartan for Patients with Heart Failure in Clinical Practice.

J Cardiovasc Pharmacol 2018 Dec 10. Epub 2018 Dec 10.

University of Alberta, Edmonton, Canada.

Little is known about the dosing and tolerability of sacubitril/valsartan (LCZ696; Entresto™, Quebec, Canada) in a non-clinical trial population. This study was conducted to evaluate the use and tolerability of sacubitril/valsartan in patients followed at a multidisciplinary heart failure clinic. We performed a retrospective chart review of 126 patients with heart failure, initiated on sacubitril/valsartan, and seen at a specialty heart failure clinic between August 1, 2015 and August 1, 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000643DOI Listing
December 2018
6 Reads

LongShengZhi Capsule Reduces Established Atherosclerotic Lesions in apoE-Deficient Mice by Ameliorating Hepatic Lipid Metabolism and Inhibiting Inflammation.

J Cardiovasc Pharmacol 2019 Feb;73(2):105-117

College of Biomedical Engineering, Hefei University of Technology, Hefei, China.

Disorders of lipid metabolism and inflammation play an important role in atherosclerosis. LongShengZhi (LSZ) capsule, a Chinese herbal medicine, has been used for treatment of patients with vascular diseases for many years. In this article, we determined the effect of LSZ on the progression of established atherosclerotic lesions in apoE-deficient (apoE) mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000642DOI Listing
February 2019
5 Reads

Therapeutic Drug Monitoring to Assess Drug Adherence in Assumed Resistant Hypertension: A Comparison With Directly Observed Therapy in Three Nonadherent Patients.

J Cardiovasc Pharmacol 2019 Feb;73(2):125

Department of Pharmacology, First Faculty of Medicine, General University Hospital in Prague, Charles University, Prague, Czech Republic. Supported by a Charles University project Progres Q25.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000637DOI Listing
February 2019
4 Reads

Mild Hypothermia Is Ineffective to Protect Against Myocardial Injury Induced by Chemical Anoxia or Forced Calcium Overload.

J Cardiovasc Pharmacol 2019 Feb;73(2):100-104

Cardiac Physiology, National Cerebral and Cardiovascular Center, Osaka, Japan.

Although hypothermia suppresses myocardial ischemia/reperfusion injury, whether it also protects the myocardium against cellular stresses such as chemical anoxia and calcium overload remains unknown. We examined the effect of mild hypothermia (33°C) on myocardial injury during ischemia/reperfusion, local administration of sodium cyanide (chemical anoxia), or local administration of maitotoxin (forced Ca overload) using cardiac microdialysis applied to the feline left ventricle. Baseline myoglobin levels (in ng/mL) were 237 ± 57 and 150 ± 46 under normothermia and hypothermia, respectively (mean ± SE, n = 6 probes each). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000639DOI Listing
February 2019
1 Read

Panax Notoginseng Saponins Attenuate Myocardial Ischemia-Reperfusion Injury Through the HIF-1α/BNIP3 Pathway of Autophagy.

J Cardiovasc Pharmacol 2019 Feb;73(2):92-99

Cardiovascular Medicine, the Affiliated Hospital of Shaoxing University, Shaoxing, China.

Background And Objective: Panax Notoginseng Saponins (PNS) is a formula of Chinese medicine commonly used for treating ischemia myocardial in China. However, its mechanism of action is yet unclear. This study investigated the effect and the mechanism of PNS on myocardial ischemia-reperfusion injury (MIRI) through the hypoxia-inducible factor 1α (HIF-1α)/bcl-2/adenovirus E1B19kDa-interacting protein3 (BNIP3) pathway of autophagy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000640DOI Listing
February 2019

Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction.

J Cardiovasc Pharmacol 2019 Feb;73(2):82-91

Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050/CNRS UMR7241, Center for Interdisciplinary Research in Biology, College de France, Paris, France.

Aims: Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI). This study evaluated effectiveness of systemic treatment with firibastat compared with AT1R blocker, losartan.

Methods And Results: MI was induced by ligation of left coronary artery in male Wistar rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000638DOI Listing
February 2019

Effect of Postablation Statin Treatment on Arrhythmia Recurrence in Patients With Paroxysmal Atrial Fibrillation.

J Cardiovasc Pharmacol 2018 Dec;72(6):285-290

2nd Department of Cardiology, University of Athens Medical School, Attikon Hospital, Athens, Greece.

Background: Statins have been proposed as a means to prevent postablation atrial fibrillation (AF) recurrences, mainly on the basis of their pleiotropic effects. The objective of this subanalysis of a prospectively randomized controlled study population of patients undergoing radiofrequency ablation for paroxysmal AF was to test the hypothesis that statin treatment is associated with longer time to recurrence.

Methods And Results: This is a subanalysis over an extended follow-up period of a prospective randomized study (ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000624DOI Listing
December 2018
4 Reads

Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.

J Cardiovasc Pharmacol 2019 Jan;73(1):3-14

Department of Anaesthesia and Intensive Care Medicine, San Gerardo Hospital, Monza, Italy.

Levosimendan is an inodilator that promotes cardiac contractility primarily through calcium sensitization of cardiac troponin C and vasodilatation via opening of adenosine triphosphate-sensitive potassium (KATP) channels in vascular smooth muscle cells; the drug also exerts organ-protective effects through a similar effect on mitochondrial KATP channels. This pharmacological profile identifies levosimendan as a drug that may have applications in a wide range of critical illness situations encountered in intensive care unit medicine: hemodynamic support in cardiogenic or septic shock; weaning from mechanical ventilation or from extracorporeal membrane oxygenation; and in the context of cardiorenal syndrome. This review, authored by experts from 9 European countries (Austria, Belgium, Czech republic, Finland, France, Germany, Italy, Sweden, and Switzerland), examines the clinical and experimental data for levosimendan in these situations and concludes that, in most instances, the evidence is encouraging, which is not the case with other cardioactive and vasoactive drugs routinely used in the intensive care unit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319595PMC
January 2019
1 Read

Late Phases of Cardioprotection During Remote Ischemic Preconditioning and Adenosine Preconditioning Involve Activation of Neurogenic Pathway.

J Cardiovasc Pharmacol 2019 Feb;73(2):63-69

Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.

Background: The role of the neurogenic pathway in early phases of cardioprotection during remote ischemic preconditioning (RIPC) and adenosine preconditioning is reported.

Aim: This study was designed to explore the involvement of the neurogenic pathway in late phases of cardioprotection during RIPC and adenosine preconditioning.

Material And Methods: Fifty-four Wistar rats were used and divided into 9 experimental groups. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9858
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000634DOI Listing
February 2019
8 Reads
2.135 Impact Factor

Detection of Putative Functional Single Nucleotide Polymorphisms in Blood Pressure Loci and Validation of Association Between Single Nucleotide Polymorphism in WBP1L and Hypertension in the Chinese Han Population.

J Cardiovasc Pharmacol 2019 Jan;73(1):48-55

Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, Jiangsu, China.

We have performed a gene-based association study and detected several important blood pressure (BP)-associated genes. In this study, we explored functional variants in these genes by bioinformatics analysis and validated the associations between the functional single nucleotide polymorphisms (SNPs) and hypertension with public data and our in-house data of 857 cases and 927 controls. We found various functional variants in the BP-associated genes, including missense mutations and phosphorylation-related SNPs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000633DOI Listing
January 2019
12 Reads

Mitochondrial Dysfunction and Apoptosis Are Attenuated on κ-Opioid Receptor Activation Through AMPK/GSK-3β Pathway After Myocardial Ischemia and Reperfusion.

J Cardiovasc Pharmacol 2019 Feb;73(2):70-81

Department of Physiology, National Key Discipline of Cell Biology, Fourth Military Medical University, Xi'an, China.

Previous studies have shown that κ-opioid receptor activation possesses cardioprotection against myocardial ischemia and reperfusion (MI/R) injury. The current study was designed to investigate whether mitochondrial dysfunction after MI/R is regulated by the κ-opioid receptor and to further explore the underlying mechanisms involved. MI/R rat model was established in vivo, and a hypoxia and reoxygenation cardiomyocytes model was used in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000635DOI Listing
February 2019
2 Reads
2.135 Impact Factor

An Orally Available NLRP3 Inflammasome Inhibitor Prevents Western Diet-Induced Cardiac Dysfunction in Mice.

J Cardiovasc Pharmacol 2018 Dec;72(6):303-307

VCU Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.

Background: A diet rich in saturated fat and sugars (Western diet, WD) induces myocardial expression of the NLRP3 inflammasome and dysfunction in mice. We therefore hypothesized that a diet enriched with an orally available NLRP3 inflammasome inhibitor could prevent WD-induced cardiac dysfunction in mice.

Methods: Ten-week-old CD-1 male mice were fed WD or standard diet (SD) for 8 weeks. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-201812000-0000
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000628DOI Listing
December 2018
7 Reads

Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems.

J Cardiovasc Pharmacol 2018 Dec;72(6):291-295

Laboratory of Pharmacology and Laboratory of Infection Diseases, F.E.S.-Cuautitlan, Universidad Nacional Autonoma de Mexico, Cuautitlan Izcalli, Mexico.

Antihypertensive pharmacological treatments focus on the use of angiotensin-converting enzyme (ACE) inhibitors, AT1 receptor antagonists, and beta-blockers as single and combined treatments. The effect of single treatments on the mRNA expression of some components of the renin-angiotensin system has been studied, but not the effect of combined treatments. This study determined the expression of the AT1, AT2, B1, and B2 receptors and of the enzymes ACE and ACE2 in hypertensive rats treated with captopril-propranolol or losartan-propranolol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000629DOI Listing
December 2018

Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance.

J Cardiovasc Pharmacol 2018 Dec;72(6):296-302

Department of Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.

Clopidogrel is an antiplatelet agent that is indicated for cardiovascular emergencies and procedures. The drug, however, is subject to response variability leading to therapy resistance. In this research, we explored the demographic, clinical, and genetic factors associated with clopidogrel resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000627DOI Listing
December 2018
2 Reads

Melatonin Attenuates Cardiac Reperfusion Stress by Improving OPA1-Related Mitochondrial Fusion in a Yap-Hippo Pathway-Dependent Manner.

J Cardiovasc Pharmacol 2019 Jan;73(1):27-39

Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

The role of OPA1-related mitochondrial fusion in cardiac reperfusion stress has remained elusive. The aim of our study is to explore whether melatonin alleviates cardiac ischemia-reperfusion (IR) injury by modulating OPA1-related mitochondrial fusion. We found that melatonin reduced infarct area, sustained myocardial function, and suppressed cardiomyocyte death during cardiac reperfusion stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000626DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319588PMC
January 2019
6 Reads

Limited Impact of β-Adrenergic Receptor Activation on Left Ventricular Diastolic Function in Rat Models of Hypertensive Heart Disease.

J Cardiovasc Pharmacol 2018 Nov;72(5):242-251

Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Background: Hypertension is a major cause of left ventricular (LV) diastolic dysfunction. Although β-adrenergic receptor (β-AR) blockers are often used to manage hypertension, the impact of β-AR activation on LV lusitropic effects and hence filling pressures in the hypertensive heart with LV diastolic dysfunction is uncertain.

Methods: Using tissue Doppler imaging and Speckle tracking software, we assessed LV function in isoflurane anesthetised spontaneously hypertensive (SHR) and Dahl salt-sensitive (DSS) rats before and after β-AR activation [isoproterenol (ISO) administration]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000620DOI Listing
November 2018
6 Reads

Protective Action of Diazoxide on Isoproterenol-Induced Hypertrophy Is Mediated by Reduction in MicroRNA-132 Expression.

J Cardiovasc Pharmacol 2018 Nov;72(5):222-230

Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del IPN, Ciudad de México, México.

Introduction And Methods: The effects of diazoxide on cardiac hypertrophy and miR-132 expression were characterized in adult rats and in cardiomyocytes. Diazoxide effects on reactive oxygen species (ROS) production and on the cAMP-response element binding (CREB) transcription factor's abundance in cardiomyocytes were also analyzed. ROS measurements used a fluorescent dye. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000619DOI Listing
November 2018
4 Reads

Resveratrol Mitigates High-Fat Diet-Induced Vascular Dysfunction by Activating the Akt/eNOS/NO and Sirt1/ER Pathway.

J Cardiovasc Pharmacol 2018 Nov;72(5):231-241

Department and Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.

We investigated whether resveratrol (RSV) can attenuate obesity and diabetes progression and improve diabetes-induced vascular dysfunction, and we attempted to delineate its underlying mechanisms. Male C57Bl/6 mice were administered a high-fat diet (HFD) for 17 weeks. Mice developed type 2 diabetes with increased body weight, hyperglycemia, hyperinsulinemia, and hyperlipidemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000621DOI Listing
November 2018
6 Reads

Seizing the Future: What's Next for the Journal of Cardiovascular Pharmacology?

Authors:
George W Booz

J Cardiovasc Pharmacol 2019 Jan;73(1):1-2

Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000630DOI Listing
January 2019

Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.

J Cardiovasc Pharmacol 2019 Jan;73(1):56-59

Interventional Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, Spain.

Background: European Guidelines on Myocardial Revascularization recommend clopidogrel loading dose added to acetylsalicylic acid in elective percutaneous coronary interventions (PCIs). However, there is few evidence supporting this recommendation and other P2Y12 inhibitors have not been tested in these patients.

Purpose: To evaluate the effectiveness and safety of different loading doses of clopidogrel and ticagrelor in patients without double antiplatelet therapy and stable coronary artery disease (SCAD) undergoing elective PCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000632DOI Listing
January 2019
6 Reads

Platelet Reactivity in Patients on Aspirin and Clopidogrel Therapy Measured by a New Bedside Whole-Blood Assay.

J Cardiovasc Pharmacol 2019 Jan;73(1):40-47

Institute of Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine University Medical Centre Düsseldorf, Düsseldorf, Germany.

Various tests are available for measuring on-treatment platelet reactivity. The pharmacologically most specific assays are time-consuming and elaborate. A highly specific and convenient assay would be desirable for clinical routine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000631DOI Listing
January 2019
2 Reads

MicroRNA-18a Expression in Female Coronary Heart Disease and Regulatory Mechanism on Endothelial Cell by Targeting Estrogen Receptor.

J Cardiovasc Pharmacol 2018 Dec;72(6):277-284

Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Coronary heart disease (CHD) is a kind of cardiovascular disease, which has been causing mortality around the world for decades. Because symptoms of CHD are different in female and male patients and these symptoms occur much later in female patients, CHD is very likely to be underdiagnosed in women. Thus, it is imperative to explore novel diagnostic method for CHD especially for women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000623DOI Listing
December 2018
1 Read

Aspirin Attenuates the Bioactivation of and Platelet Response to Vicagrel in Mice.

J Cardiovasc Pharmacol 2018 Nov;72(5):252-258

Department of Pharmacology, College of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

Vicagrel, a novel acetate analogue of clopidogrel, exerts more potent antiplatelet effect than clopidogrel in rodents. Relevant evidence indicated that aspirin and vicagrel are the drug substrate for carboxylesterase 2. Accordingly, it is deduced that concomitant use of aspirin could attenuate the bioactivation of and platelet response to vicagrel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000622DOI Listing
November 2018
1 Read

Copaiba Oil Attenuates Right Ventricular Remodeling by Decreasing Myocardial Apoptotic Signaling in Monocrotaline-Induced Rats.

J Cardiovasc Pharmacol 2018 Nov;72(5):214-221

Department of Physiology, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

There is an increase in oxidative stress and apoptosis signaling during the transition from hypertrophy to right ventricular (RV) failure caused by pulmonary arterial hypertension (PAH) induced by monocrotaline (MCT). In this study, it was evaluated the action of copaiba oil on the modulation of proteins involved in RV apoptosis signaling in rats with PAH. Male Wistar rats (±170 g, n = 7/group) were divided into 4 groups: control, MCT, copaiba oil, and MCT + copaiba oil. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9859
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000617DOI Listing
November 2018
5 Reads

Metformin Regulates the Expression of SK2 and SK3 in the Atria of Rats With Type 2 Diabetes Mellitus Through the NOX4/p38MAPK Signaling Pathway.

J Cardiovasc Pharmacol 2018 Nov;72(5):205-213

Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China.

We previously found that metformin regulates the ion current conducted by the small conductance calcium-activated potassium channels (SK channels) in the atria of rats with type 2 diabetes mellitus (T2DM) as well as the mRNA and protein expression of the SK2 and SK3 subtypes of SK channels. In this study, we hypothesized that the nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4)/p38 mitogen-activated protein kinase (p38MAPK) signaling pathway was involved in the metformin-mediated regulation of SK2 and SK3 expression in the atria of rats with T2DM. We randomly divided Wistar rats into the control group, the untreated T2DM group, the metformin-treated group, the group receiving subcutaneous injections of the nicotinamide adenine dinucleotide phosphate oxidase (NOX) inhibitor diphenyleneiodonium (DPI), and the group receiving tail vein injections of the p38MAPK agonist anisomycin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000615DOI Listing
November 2018
3 Reads

Metoprolol and Nebivolol Prevent the Decline of the Redox Status of Low-Molecular-Weight Aminothiols in Blood Plasma of Rats During Acute Cerebral Ischemia.

J Cardiovasc Pharmacol 2018 Oct;72(4):195-203

Department of Molecular and Cell Pathophysiology, Institute of General Pathology and Pathophysiology, 125315, Russia, Moscow, Baltiyskaya str., 8.

Cerebral ischemia has previously been shown to cause a systemic decrease in levels of the reduced forms of low-molecular-weight aminothiols [cysteine (Cys), homocysteine (Hcy), and glutathione (GSH)] in blood plasma. In this study, we examined the effect of beta-adrenergic receptor (β-AR) antagonists metoprolol (Met) and nebivolol (Neb) on the redox status of these aminothiols during acute cerebral ischemia in rats. We used a model of global cerebral ischemia (bilateral occlusion of common carotid arteries with hypotension lasting for 10 minutes). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000616DOI Listing
October 2018
6 Reads

Effect of Cannabinoid Receptor Agonists on Isolated Rat Atria.

J Cardiovasc Pharmacol 2018 Oct;72(4):191-194

Department of Pharmacology and Toxicology, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.

Cannabinoid CB2 receptor agonists are under investigation for clinical use. At the same time, synthetic cannabinoids have been implicated in a number of deaths. One cause of death is thought to be cardiac arrest subsequent to extreme tachycardia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000613DOI Listing
October 2018
1 Read

Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.

J Cardiovasc Pharmacol 2018 Oct;72(4):186-190

Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University, Medical Center Dusseldorf, Dusseldorf, Germany.

Prasugrel and ticagrelor are recommended over clopidogrel in patients with ST-elevation myocardial infarction (STEMI). In this registry analysis, we compared efficacy and safety of ticagrelor and prasugrel P2Y12 inhibition in patients with STEMI. We included 318 patients in this single-center analysis. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9860
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000609DOI Listing
October 2018
25 Reads
2.135 Impact Factor

Dofetilide-Associated QT Prolongation: Total Body Weight Versus Adjusted or Ideal Body Weight for Dosing.

J Cardiovasc Pharmacol 2018 Sep;72(3):161-165

Geisel School of Medicine at Dartmouth, Hanover, NH.

Dofetilide is an antiarrhythmic drug with dosing based on the Cockcroft-Gault formula using total body weight (TBW). We investigated the impact of calculating dofetilide dose using adjusted body weight (ABW) or ideal body weight (IBW) on subsequent dose reduction or discontinuation. We conducted a retrospective review of 265 patients admitted to an academic medical center for initiation of dofetilide using TBW. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000610DOI Listing
September 2018
6 Reads

Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.

J Cardiovasc Pharmacol 2018 Sep;72(3):153-160

John Paul II Hospital, Cracow, Poland.

Aims: Thrombocytopenia was one of the exclusion criteria in randomized trials in which non-vitamin K antagonist oral anticoagulants (NOACs) were tested. The safety of NOACs in patients with atrial fibrillation (AF) and thrombocytopenia remains unclear.

Methods: We studied 62 patients with AF aged from 53 to 85 (mean 70. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-201809000-0000
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000607DOI Listing
September 2018
14 Reads

Simvastatin Treatment Protects Myocardium in Noncoronary Artery Cardiac Surgery by Inhibiting Apoptosis Through miR-15a-5p Targeting.

J Cardiovasc Pharmacol 2018 Oct;72(4):176-185

Division of Cardiac Surgery, Heart Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China.

Simvastatin treatment is cardioprotective in patients undergoing noncoronary artery cardiac surgery. However, the mechanisms by which simvastatin treatment protects the myocardium under these conditions are not fully understood. Seventy patients undergoing noncoronary cardiac surgery, 35 from a simvastatin treatment group and 35 from a control treatment group, were enrolled in our clinical study. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9860
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000611DOI Listing
October 2018
16 Reads
2.130 Impact Factor

C1q/TNF-Related Protein 9 Inhibits THP-1 Macrophage Foam Cell Formation by Enhancing Autophagy.

J Cardiovasc Pharmacol 2018 Oct;72(4):167-175

Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.

During the pathogenesis of early atherosclerosis, lipid-loaded macrophages are involved in plaque development and progression. As a novel adipokine, C1q/tumor necrosis factor-related protein-9 (CTRP9) has beneficial effects in cardiovascular disease. However, previous reports have not studied whether the formation of macrophage foam cell induced by oxidized low-density lipoprotein (ox-LDL) is affected by CTRP9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181274PMC
October 2018
3 Reads
2.130 Impact Factor

Irisin Protects Heart Against Ischemia-Reperfusion Injury Through a SOD2-Dependent Mitochondria Mechanism.

J Cardiovasc Pharmacol 2018 Dec;72(6):259-269

Department of Cardiology, Daping Hospital, Third Military Medical University, Chongqing Institute of Cardiology, Chongqing, People's Republic of China.

Irisin, a muscle-origin protein derived from the extracellular domain of the fibronectin domain-containing 5 protein (FNDC5), has been shown to modulate mitochondria welfare through paracrine action. Here, we test the hypothesis that irisin contributes to cardioprotection after myocardial infarction by preserving mitochondrial function in cardiomyocytes. Animal model studies show that intravenous administration of exogenous irisin produces dose-dependent protection against ischemia/reperfusion (I/R)-induced injury to the heart as reflected by the improvement of left ventricular ejection fraction and the reduction in serum level of cTnI (n = 15, P < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000608DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283696PMC
December 2018
18 Reads
2.130 Impact Factor

A Few Initial Thoughts on Receiving the Baton.

Authors:
George W Booz

J Cardiovasc Pharmacol 2018 Jul;72(1)

Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000601DOI Listing
July 2018
1 Read

Passing the Baton.

Authors:
Michael R Rosen

J Cardiovasc Pharmacol 2018 Jul;72(1)

Department of Pharmacology, Columbia University, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000585DOI Listing